Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6690196.pdf
Reference45 articles.
1. Allred, D. C., Clark, G., Tandon, A., Schnitt, S. J., Gilchrist, K. W., Osborne, C. K., Tormey, D. C. & McGuire, W. L. (1992). HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599–605.
2. Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hinna, W., Lickley, L., Wilkinson, R., Qizlbash, A., Ambus, U., Lipa, M., Weizel, H., Katz, A., Baida, M., Mariz, S., Stoik, G., Dacamara, P., Strongitharm, D., Geddie, W. & McCready, D. (1998). neu/erbB2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16: 1340–1349.
3. Archer, S. G., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I. O., Blamey, R. W., Nicholson, R. I. & Robertson, J. F. (1995). Expression of ras p21, p53 and c-erbB2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259–1266.
4. Barnes, D. M., Lammie, G. A., Millis, R. R., Gullick, W. J., Allen, D. S. & Altman, D. G. (1988). An immunohistochemical evaluation of c-erbB2 expression in human breast carcinoma. Br J Cancer 58: 448–452.
5. Barnes, D. M., Millis, R. R., Beex, LVAM, Thorpe, S. M. & Leake, R. E. (1998). Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer 34: 1677–1682.
Cited by 182 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer;Cancer Treatment Reviews;2024-07
2. Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance;Drugs - Real World Outcomes;2024-06-16
3. Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery;Molecular Imaging and Biology;2023-10-16
4. Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer;Endocrine-Related Cancer;2022-08-01
5. Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor– and ErbB2-positive Breast Cancer;Clinical Cancer Research;2022-03-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3